Long-Term Safety Study Confirms Withania Somnifera Benefits for Aging Adults

Could WS Supplementation Offer Reliable Long-Term Safety?

The 180-day clinical trial of standardized Withania somnifera (WS) root extract has demonstrated a robust safety profile in healthy adults, addressing a critical gap in our understanding of this widely used herb's long-term effects. The double-blind, placebo-controlled study involving 40 participants (predominantly male) aged 50-70 years found no significant adverse events or abnormalities across a comprehensive range of clinical parameters. This investigation, registered with the Clinical Trial Registry-India (CTRI/2023/11/059395), provides valuable evidence for healthcare professionals considering botanical interventions for their patients.

The randomized trial, conducted at Lokmanya Medical Research Centre in Pune, evaluated USP-NF standardized WS root extract (brand name LongeFera) containing not less than 2.5% w/w total withanolides at a dose of 200 mg twice daily. This standardization is particularly noteworthy as it addresses concerns about product consistency that often plague herbal supplement research. The study's meticulous attention to quality control, including HPLC-PDA analysis of the extract, ensures that findings can be reliably attributed to a well-characterized intervention rather than variable plant material. The investigators performed comprehensive safety assessments including hematological parameters, hepatic and renal function tests, lipid profiles, thyroid function, glycemic status, immune markers, cardiac biomarkers, and reproductive hormones, supplemented by ECG and chest X-ray evaluations at baseline and after 180 days of supplementation.

What Do Biomarker Changes Reveal About WS Effects?

Perhaps most intriguing among the findings was a statistically significant 17.78% increase in testosterone levels among male participants in the WS group, contrasting with an 11.15% reduction observed in the placebo group. This hormonal effect aligns with traditional Ayurvedic applications of WS and may explain some of its reported benefits for vitality and muscle strength. The mechanism likely involves stimulation of the hypothalamic-pituitary-gonadal axis, potentially increasing luteinizing hormone secretion and subsequent testosterone production. Could this finding position WS as a natural option for addressing age-related testosterone decline in men? The clinical significance of this moderate increase deserves further investigation, particularly regarding functional outcomes such as muscle mass, strength, and quality of life measures.

Another significant finding was the substantial reduction in inflammatory markers, with C-reactive protein (CRP) decreasing by 51.1% in the WS group compared to a 27.77% reduction in the placebo group. Similarly, NT-proBNP, a cardiac biomarker associated with ventricular stress, decreased by 28.70% in the WS group while slightly increasing in the placebo group. These anti-inflammatory effects may be attributed to withanolides like withaferin-A, which have been shown to inhibit inflammatory pathways including TNF-α, IL-1β, and NF-κB. The reduction in these biomarkers suggests potential cardiovascular benefits that warrant exploration in populations with elevated inflammatory markers or cardiovascular risk factors. How might these anti-inflammatory properties translate to clinical outcomes in patients with chronic inflammatory conditions or subclinical cardiovascular disease?

Glycemic parameters showed favorable trends in the WS group, with fasting insulin levels significantly decreasing while fasting blood glucose remained stable. In contrast, the placebo group experienced a significant increase in fasting blood glucose. The study reported that among participants with prediabetes or diabetes at baseline, those receiving WS showed improvement, with three normalizing and one remaining diabetic. Conversely, in the placebo group, more participants progressed to prediabetic status. These observations suggest potential metabolic benefits that align with previous research on WS and glucose regulation, though the mechanisms require further elucidation. The interaction between improved insulin sensitivity, reduced inflammation, and hormonal modulation presents an intriguing area for future research, particularly in metabolic syndrome or prediabetic populations.

Is Extended WS Use Safe Across Vital Parameters?

Importantly, all safety parameters including hematological, hepatic, renal, and thyroid function remained within normal clinical ranges throughout the study period. While some statistically significant changes were observed in certain parameters (such as decreased T3 and T4 thyroid hormone levels), these remained within physiological ranges and were not considered clinically significant. The absence of adverse effects on vital organ function, combined with excellent tolerability reported by all participants, reinforces the safety profile of standardized WS root extract for extended use. This comprehensive safety assessment addresses concerns raised by some European regulatory bodies, such as Denmark's DVFA, which had previously restricted WS due to safety uncertainties.

Despite these promising findings, several limitations must be considered. The study population was predominantly male (36 males, 4 females), limiting the generalizability of findings to women. The small sample size, while adequate for safety assessment, may not have captured less common adverse effects. Additionally, the study focused primarily on safety rather than efficacy endpoints, though several biomarker improvements suggest potential benefits. Would a larger study with more diverse participants and specific efficacy outcomes reveal additional benefits or identify subpopulations that respond differently to WS supplementation? How might genetic variations in metabolism of botanical compounds influence individual responses?

How Might These Findings Shape Clinical Practice?

This study builds upon previous shorter-term safety assessments of WS, including work by Raut et al. (2012), Vaidya et al. (2024), and Verma et al. (2021), extending the safety profile to a much longer duration. The findings are particularly relevant given the growing global market for WS products, projected to reach $1.187 billion by 2032. As consumers increasingly turn to botanical supplements for health support, evidence-based safety data becomes essential for healthcare providers advising patients on complementary approaches. What regulatory implications might these findings have for markets where WS has faced restrictions due to safety concerns? Could standardized extracts with documented safety profiles receive different regulatory consideration than unstandardized preparations?

For clinicians considering WS as a potential recommendation, this study provides reassurance regarding its long-term safety when using standardized root extract. The observed benefits for testosterone levels, inflammatory markers, and glycemic parameters suggest potential applications beyond traditional Ayurvedic uses, though these require confirmation in dedicated efficacy trials. As with any supplement, individual patient factors should guide recommendations, and monitoring remains prudent, particularly when combining with pharmaceutical interventions. The study's emphasis on root-only extract is noteworthy, as traditional Ayurvedic practice specifically recommends against oral use of WS leaves due to potential toxicity concerns, a distinction that may not be clear in all commercial products.

In conclusion, this 180-day randomized trial provides substantial evidence for the safety and tolerability of standardized WS root extract in healthy adults, while suggesting potential benefits for hormonal health, inflammation reduction, and metabolic function. The findings support its consideration as a safe nutraceutical intervention, though larger studies with more diverse populations are needed to fully characterize its efficacy and identify optimal applications in clinical practice. Could Withania somnifera emerge as an evidence-based option for addressing age-related inflammatory and hormonal changes? This study takes an important step toward answering that question with methodological rigor and comprehensive safety assessment.

Summary

A 180-day randomized, double-blind, placebo-controlled clinical trial has demonstrated a robust safety profile for standardized Withania somnifera root extract in healthy adults aged 50-70 years. The study, conducted at Lokmanya Medical Research Centre in Pune and involving 40 participants, evaluated a USP-NF standardized extract containing at least 2.5% withanolides at a dose of 200 mg twice daily. Comprehensive safety assessments including hematological, hepatic, renal, thyroid, cardiovascular, and metabolic parameters revealed no significant adverse events throughout the six-month supplementation period. Beyond safety confirmation, the study revealed several statistically significant biomarker improvements in the WS group compared to placebo: male participants experienced a 17.78% increase in testosterone levels, C-reactive protein decreased by 51.1%, NT-proBNP cardiac biomarker decreased by 28.70%, and fasting insulin levels improved while blood glucose remained stable. Among participants with prediabetes or diabetes at baseline, those receiving WS showed metabolic improvement, with three normalizing their status. All vital organ function parameters remained within normal clinical ranges, with excellent tolerability reported by all participants. The study addresses critical gaps in understanding long-term safety of this widely used Ayurvedic herb and provides evidence-based data for healthcare professionals considering botanical interventions. Study limitations include a predominantly male population and relatively small sample size, suggesting the need for larger trials with diverse participants to fully characterize efficacy and identify optimal clinical applications. These findings support consideration of standardized WS root extract as a safe nutraceutical intervention with potential benefits for hormonal health, inflammation reduction, and metabolic function in aging adults.